47.42

0.13% 0.06

Rapport Therapeutics Inc (RAPP)

Overview News Price History Discussions Forecast

Rapport Therapeutics Inc stock is traded at $47.42, with a volume of 159.83K. It is up +0.13% in the last 24 hours and up +14.38% over the past month. Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.

Previous Close:

$47.36

Open:

$47

24h Volume:

159.83K

Relative Volume:

0.46

Market Cap:

$2.28B

Revenue:

Net Income/Loss:

$-107.28M

P/E Ratio:

-18.22

EPS:

-2.6031

Net Cash Flow:

$-80.71M

1W Performance:

+4.24%

1M Performance:

+14.38%

6M Performance:

+69.78%

1Y Performance:

+217.40%

1-Day Range:

$46.37

$47.64

1-Week Range:

$45.30

$49.50

52-Week Range:

$13.86

$49.50

Rapport Therapeutics Inc Stock (RAPP) Company Profile

Name

Rapport Therapeutics Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

857-321-8020

Address

99 HIGH STREET, BOSTON

Employee

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

RAPP's Discussions on Twitter

Compare RAPP vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RAPP Rapport Therapeutics Inc	47.42	2.29B	0	-107.28M	-80.71M	-2.6031
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-10-26	Initiated	Raymond James	Strong Buy
Feb-02-26	Initiated	Wells Fargo	Overweight
Nov-19-25	Initiated	BTIG Research	Buy
Sep-16-25	Initiated	Truist	Buy
Aug-06-25	Initiated	H.C. Wainwright	Buy
Apr-08-25	Initiated	Citizens JMP	Mkt Outperform
Jul-02-24	Initiated	Jefferies	Buy
Jul-02-24	Initiated	Stifel	Buy
Jul-02-24	Initiated	TD Cowen	Buy

View All

Rapport Therapeutics Inc Stock (RAPP) Latest News

Aug 14, 2026

Brokers Offer Predictions for RAPP Q1 Earnings - MarketBeat

Aug 14, 2026

Aug 12, 2026

Rapport Therapeutics (NASDAQ:RAPP) CEO Abraham Ceesay Sells 28,958 Shares - MarketBeat

Aug 12, 2026

Abraham Ceesay Sells 22,541 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock - MarketBeat

Aug 12, 2026

Rapport Therapeutics (RAPP) CEO Abraham Ceesay sells 51,499 shares via 10b5-1 plan - Stock Titan

Aug 12, 2026

Rapport Therapeutics (NASDAQ:RAPP) Given New $66.00 Price Target at HC Wainwright - MarketBeat

Aug 12, 2026

Rapport Therapeutics (NASDAQ:RAPP) Sets New 1-Year HighTime to Buy? - MarketBeat

Aug 12, 2026

Aug 11, 2026